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Edited by Richard MaraisAbstract We examined the eﬀects of prostaglandin E (PGE)
receptor subtype EP4 antagonist on bone metastasis of cancer
to clarify PGE’s role in bone metastasis. Metastatic regions
were detected in femurs accompanying severe bone loss in mice
injected with B16 malignant melanoma cells. Administration of
EP4 antagonist restored the bone loss induced by B16 mela-
noma. Adding B16 cells induced osteoclast formation in the
coculture of bone marrow cells and osteoblasts without any
exogenous bone-resorbing factor, and EP4 antagonist com-
pletely suppressed the osteoclast formation induced by B16 cells.
Therefore, EP4 antagonist is a possible candidate for the therapy
of bone metastasis of cancer.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Bone metastasis of cancer is accompanied by severe bone
destruction with increased bone resorption. Some cancer cells
are known to release soluble bone-resorbing factors such as
parathyroid hormone-related protein (PTHrP), which may be
one of the candidates for regulators in tumor-induced osteoly-
sis [1,2]. On the other hand, cell-to-cell interaction between
cancer and host cells is thought to be involved in the mecha-
nism of bone resorption in the region of cancer metastasis.
We have reported that bone tissue with metastasis of breast
cancer highly expressed receptor activator of NFjB ligand
(RANKL), a key molecule for osteoclast diﬀerentiation, and
that the expression of RANKL in osteoblasts was enhanced
by contact with the cancer cells in vitro [3], suggesting that
the regulation of host cells is a candidate therapeutic approach
for bone metastasis of cancer.Abbreviations: PGE, prostaglandin E; RANKL, receptor activator of
NFjB ligand; TRAP, tartrate-resistant acid phosphatase; COX, cyclo-
oxygenase; PTHrP, parathyroid hormone-related protein; NSAID,
non-steroidal anti-inﬂammatory drugs; BMD, bone mineral density;
BV/TV, bone volume/tissue volume; Tb.Sp, trabecular separation;
Tb.Th, trabecular thickness; ES/BS, erosion surface/bone surface;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase
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doi:10.1016/j.febslet.2007.01.005Prostaglandin E2 (PGE2) is produced in bone mainly by
osteoblasts and stimulates bone resorption. There are four sub-
types of PGE receptors, designated EP1, EP2, EP3, and EP4,
that are encoded by diﬀerent genes and expressed diﬀerently
in each tissue [4–7]. The intracellular signaling diﬀers among
the receptor subtypes; EP1 is coupled to calcium mobilization,
EP3 inhibits adenylate cyclase, whereas both EP2 and EP4
stimulate adenylate cyclase in various types of cells. Using
knockout mice of respective EP and speciﬁc EP agonists, we
reported that PGE2 stimulates bone resorption mainly by
EP4 [8,9]. EP4 agonist greatly stimulated the expression of
RANKL in osteoblasts and induced osteoclast formation in
mouse bone marrow cultures [8]. Therefore, PGE2 may stimu-
late bone resorption by the RANKL-dependent mechanism
via EP4 receptors expressed in osteoblasts.
Previous studies suggest a possible correlation between can-
cer growth and prostaglandins (PGs). Null mutation of the cy-
clo-oxygenase (COX)-1, COX-2, and EP2 genes showed
reduced intestinal polyp formation inMinmice with amutation
in the Apc gene [10,11]. Non-steroidal anti-inﬂammatory drugs
(NSAIDs) have been reported to reduce the risk of breast can-
cer and colon carcinogenesis [12,13]. Some malignant tumor
cells highly express COX-2 in vivo, and COX-induced PGE2
production enhances the tumorigenesis of cancer [14]. Recently,
Ma et al. [15] reported that EP4 antagonist inhibits the PGE2-
induced chemotactic response and lung metastasis of breast
cancer cells. Previous studies have shown that the expression
of COX-2 was elevated in host stromal cells and osteoblasts
in the region of bone metastasis of cancer [16]. Therefore, sup-
pression of the PGE signal in host cells may be a possible way to
improve severe osteolysis due to the bone metastasis of cancer.
In the present study, we examined the eﬀects of EP4 antag-
onist on bone destruction due to the metastasis of malignant
melanoma, and show that blockage of the EP4 signal is a
new therapeutic approach for bone destruction due to cancer
metastasis.2. Materials and methods
2.1. Intracardiac injection of B16 cells in C57BL/6 mice
B16 cells were cultured in Dulbecco’s Modiﬁed Eagle Medium
(DMEM), supplementedwith 10% fetal calf serum (FCS) at 37 Cunder
5% CO2 in air. B16 cells (2 · 105 cells) were suspended in 0.1 mL PBS
and injected into the left heart ventricle of 6-week-old male C57BL/6
mice (Shizuoka, Japan) under anesthesia with pentobarbital. Animals
were kept in our clean animal facilities for 12 days. EP4 antagonist,
AE3-208, was prepared in Ono pharmaceutical Co. Ltd. The Ki valuesblished by Elsevier B.V. All rights reserved.
Fig. 1. Intracardiac injection of B16 cells into C57BL/6 mice causes
severe osteolysis due to bone metastasis. (A) C57BL/6 mice were
injected with or without B16 cells and the femurs were collected from
mice on 12 days after injection. Representative pictures of the femur
are shown. (B) The expression of RANKL, COX-1, and COX-2
mRNA was analyzed by RT-PCR using total RNA collected from the
femur with or without B16 metastasis. (C) The bone marrow ﬂuid was
prepared using 1 mL of PBS, and the concentration of PGE2 in the
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radio-labeled ligand binding to the respective prostanoid receptor are
1.3, 30, 790, and 2400 nM for EP4, EP3, FP, and TP, respectively,
and more than 10000 nM for the other prostanoid receptors [17]. EP4
antagonist (10 mg/kg of body weight/day) was administered by oral ga-
vage to mice from days 0 to 11, and the femurs were collected from the
mice on day 12. The dose usage of EP4 antagonist was referred previous
study for experimental mouse colitis model [17]. As a control group,
mice were administered distilled water only. All experimental proce-
dures were performed in accordance with institutional guideline for ani-
mal research, and approved by the Committee for Animal Research in
Tokyo University of Agriculture and Technology.
2.2. Measurement of bone mineral density
The bone mineral density (BMD) of the femurs was measured by
dual X-ray absorptiometry (model DCS-600R; Aloka), as previously
reported [18]. The bone mineral content of the femurs was closely cor-
related with the ash weight [18]. The BMD was calculated by dividing
the bone mineral content of the measured area by the area.
2.3. Measurement of PGE2 content in bone marrow supernatant
Six-week-old C57BL/6 mice were injected with B16 cells and the
femurs and tibiae were collected 12 days after the injection. To obtain
the bone marrow supernatant, bone marrow cells and trabecular bone
fragments were collected with 1 mL of PBS from the femurs and tibiae,
as previously reported [19]. After centrifugation to remove the cells
and bone fragments, the supernatant was collected for the measure-
ment of PGE2. The concentration of PGE2 in the bone marrow super-
natant was determined using an enzyme immunoassay (EIA;
Amersham Biosciences) with the standard curve in the range of 50–
6400 pg/mL.
2.4. Histological analysis of the femoral trabecular bone
The distal metaphysis of the femur was ﬁxed with 70% ethanol and
embedded in glycol methacrylate, and undecalciﬁed 3-lm sections were
prepared and stained for hematoxylin–eosin (HE), as reported previ-
ously [18]. The trabecular bone volume density (bone volume/tissue
volume [BV/TV]), trabecular separation (Tb.Sp), trabecular thickness
(Tb.Th), and erosion surface/bone surface (ES/BS) were determined
in the trabecular bone at the secondary spongiosa of the distal meta-
physis in femurs [18].
2.5. RT-PCR analysis
Total RNA was extracted from the femur and cocultured mouse
osteoblasts and bone marrow cells, using the acid guanidium–phe-
nol–chloroform method [20]. cDNA was synthesized from 5 lg of total
RNA by reverse transcriptase (Superscript II Preampliﬁcation System,
Invitrogen, Carlsbad, CA) and ampliﬁed via PCR. The primers in PCR
for the mouse RANKL, COX-1, COX-2, EP4, and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) genes were used as reported pre-
viously [20]. The PCR product was run on a 1.5% agarose gel and
stained with ethidium bromide.
2.6. Osteoclast formation in coculture of mouse bone marrow cells
and osteoblasts
Primary osteoblastic cells were isolated from 2-day-old mouse calvar-
iae, as described previously [18]. Bone marrow cells (3 · 106 cells) were
isolated from 6-weeks-old mice and cocultured with the primary osteo-
blastic cells (1 · 104 cells) in 1 mL of aMEMcontaining 10%FCSwith a
physiological concentration (10 pM) of 1a,25-dihydroxyvitaminD3. To
examine the eﬀects of B16 cells on osteoclast formation, B16 cells were
ﬁxed with 4% paraformaldehyde, washed three times with PBS, and
added to the cocultures. After being cultured for 7 days, the cells were
stained for tartrate-resistant acid phosphatase (TRAP), and TRAP-po-
sitive multinucleated cells were counted as osteoclasts. To extract total
RNA for RT-PCR analysis, the cells adhering to the well surface were
lysed on day 4. Data are expressed as the means ± S.E.M. The signiﬁ-
cance of diﬀerences was analyzed using Student’s t-test.bone marrow ﬂuid was determined using an EIA. Signiﬁcantly
diﬀerent from control mice without B16 cell injection, *P < 0.05. Data
are expressed as the means ± S.E.M. of 6–7 mice. (D) The BMD was
measured at the total area of the femur. Signiﬁcantly diﬀerent from
control mice without B16 cell injection, **P < 0.01. Data are expressed
as the means ± S.E.M. of 6–7 mice.2.7. Colony formation of B16 cells
B16 cells (3 · 102 cells) were cultured in 2 mL of DMEM containing
10% FCS on six-well plates. The cultures were maintained by replacing
the old medium to fresh medium for every 3 days. After being culturedfor 7 days, the cells adhering to the well surface were stained for crystal
violet to visualize colonies. The number of B16 cell colonies was
counted using microscopy.3. Results
3.1. Bone loss and increased PGE2 production in bone with
metastasis of malignant melanoma cells
We ﬁrst established the experimental model of bone meta-
stasis of cancer cells using mouse B16 melanoma, and mea-
sured the bone density of femurs. B16 cells were injected into
the left heart ventricle of C57BL/6 mice and the femurs were
collected from the mice to measure BMD of the femurs. Since
B16 cells actively produced melanin, the metastasis region
could be detected as black in the femurs on day 12 after the
injection of B16 cells (Fig. 1A). The BMD was signiﬁcantly
reduced in mice with bone metastasis of B16 compared with
control mice (Fig. 1D). In RT-PCR using total RNA extracted
from femur, the mRNA expression of RANKL and COX-2
was elevated in the femur with metastasis of B16 cells com-
pared with control (Fig. 1B). To examine the possible involve-
ment of PGE2 production in bone loss due to metastasis, we
collected bone marrow supernatant from the femur and tibia,
and measured the PGE2 level. The level of PGE2 in bone
Fig. 2. Oral administration of EP4 antagonist suppresses osteolysis
due to bone metastasis of B16 cells. C57BL/6 mice were injected with
or without B16 cells and then EP4 antagonist was administered by oral
gavage to mice injected with or without B16 cells for 11 days. Control
mice injected with or without B16 cells were administered with distilled
water. The femurs were collected from mice 12 days after injection.
The BMD was measured at the total area of the femur. Signiﬁcantly
diﬀerent, *P < 0.05. Data are expressed as the means ± S.E.M. of 6–8
mice.
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metastasis (Fig. 1C). These results suggest that PGE2, a potent
bone-resorbing factor, produced by bone with metastasis is in-
volved in the mechanism of bone loss due to the metastasis of
B16 cells.
3.2. Eﬀects of EP4 antagonist on BMD of femur with
metastasis of B16 cells
In the experimental model of bone metastasis using B16 mel-
anoma cells, we examined the eﬀects of EP4 antagonist on fem-
oral BMD in mice with metastasis. When EP4 antagonist was
orally administered to mice injected with B16 cells, decreased
BMD was signiﬁcantly restored (Fig. 2). Administration of
EP4 antagonist into mice without injection of B16 cells had
no eﬀect on femoral BMD.
3.3. Histological analysis of bone loss due to metastasis of
B16 cells
In the section stained for HE, metastatic tumor cells ﬁlled
the bone marrow cavity and trabecular bone area in the distal
femoral metaphysis of mice injected with B16 cells (Fig. 3A).
Trabecular bone was surrounded by tumor cells, and was
markedly destroyed in these mice (Fig. 3B). Sections prepared
from mice treated with EP4 antagonist showed a reduced area
of tumor metastasis, and trabecular bone loss was attenuated
(Fig. 3A and B). Next, we performed histological analysis of
trabecular bone using the section of the distal femoral metaph-
ysis. In mice injected with B16 cells, BV/TV and Tb.Th were
signiﬁcantly reduced, whereas Tb.Sp increased compared with
control mice without the injection of B16 cells (Fig. 3C–E).
The increase in Tb.Sp indicates that osteoclastic bone resorp-
tion was stimulated, resulting in enhanced intertrabecular
space. In fact, ES/BS signiﬁcantly increased in the trabecular
bone obtained from mice with bone metastasis compared with
control mice without metastasis (Fig. 3F). By the administra-
tion of EP4 antagonist to mice injected with B16 cells, the
reduced BV/TV was signiﬁcantly elevated, and the changesof Tb.Th, Tb.Sp, and ES/BS were restored. Therefore, the
metastasis of B16 induced the loss of trabecular bone by in-
creased bone resorption, and EP4 antagonist attenuated bone
destruction due to cancer metastasis.3.4. Osteoclast formation induced by B16 melanoma cells in vitro
To examine the action mechanism of EP4 antagonist in bone
resorption due to cancer metastasis, we performed the cocul-
tures of bone marrow cells and osteoblasts in the presence or
absence of B16 cells ﬁxed with paraformaldehyde. By the use
of ﬁxed-B16 cells instead of live B16 cells, we excluded the pos-
sibility of the inﬂuence of soluble factor(s) produced by B16
cells, prevented the growth of B16, and speciﬁcally focused
on the cell-to-cell interaction between cancer cells and host
osteoblasts in the cocultures. B16 cells markedly induced
osteoclast formation in the cocultures, and adding EP4 antag-
onist completely suppressed osteoclast formation (Fig. 4A).
COX-2 inhibitor, NS398, and indomethacin also suppressed
osteoclast formation induced by B16 cells. The level of
PGE2 was markedly elevated by the cocultures with B16,
and suppressed by NS398 and indomethacin, but not by EP4
antagonist (Fig. 4B). The expression of RANKL mRNA was
enhanced by coculture with B16, and the expression was sup-
pressed by EP4 antagonist (Fig. 4C). NS398 and indomethacin
also suppressed the expression of RANKL mRNA in the
cocultures. PGE2 is produced by osteoblasts after cell-to-cell
interaction with B16 cells, and plays a critical role in tumor-in-
duced osteoclastogenesis, and that EP4 antagonist acts on
osteoblasts to block the binding of PGE2 to EP4 receptors ex-
pressed in osteoblasts following the suppression of osteoclast
formation.3.5. Eﬀects of PGE2 and EP4 antagonist on cell growth of
B16 melanoma in vitro
To examine the eﬀects of PGE2 and EP4 antagonist on the
proliferation of B16 cells, we added PGE2 and EP4 antagonist
to the cultures of B16 cells, and counted the number of colo-
nies on day 7. Neither PGE2 nor EP4 antagonist inﬂuenced
the number of B16 colonies (Fig. 5A). We further examined
whether B16 cells expressed COX-2 and EP4. In RT-PCR,
the expression of COX-1, COX-2, and EP4 mRNAs was only
detected in mouse osteoblasts but not in B16 cells (Fig. 5B). In
addition, PGE2 could not be detected in the conditioned
medium of B16 cell cultures (data not shown). Therefore, it
is unlikely that the growth of B16 is directly regulated by
PGE2.4. Discussion
In the present study, the administration of EP4 antagonist
clearly suppressed osteolysis in the region of bone metastasis
in mice injected with malignant melanoma B16 cells (Figs. 2
and 3). We suggest that local production of PGE2 in bone
and bone marrow may contribute to the loss of trabecular
bone in femurs with metastasis. To deﬁne whether PGE2 acts
on B16 cells to regulate cell growth, we examined the eﬀects of
PGE2 and/or EP4 antagonist on colony formation of B16 cells
in vitro. Neither PGE2 nor EP4 antagonist aﬀected the cell
growth of B16 cells (Fig. 5A). Recently, Xia et al. reported that
Fig. 3. Histological analysis of femurs from mice injected with or without B16 cells. The femurs were collected from mice injected with or without
B16 cells, as described in Fig. 2, and sections of the distal metaphysis were prepared. HE staining of histological sections of the femur and
representative ﬁelds are shown at a low magniﬁcation (A), and high magniﬁcation (B). In the control section without B16 injection, bone marrow
cells (BM) and the trabecular bone (TB) were normal. In the metastasised section with B16 injection, B16 cells (Tumor) ﬁlled the bone marrow cavity
and replaced the cellular elements. Using the HE-stained section shown in panels A and B, histomorphometric analyses were performed to calculate
BV/TV (C), Tb.Th (D), Tb.Sp (E), and ES/BS (F). Signiﬁcantly diﬀerent, *P < 0.05, **P < 0.01, ***P < 0.001. Data are expressed as the
means ± S.E.M. of four mice.
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say [21]. In addition, B16 cells did not express COX-2 and EP4mRNAs (Fig. 5B). These results suggest that PGE2 produced
by host cells act on osteoblasts in bone tissue to stimulate bone
Fig. 5. Eﬀects of PGE2 and EP4 antagonist on colony formation of
B16 cells in vitro. (A) B16 cells (3 · 102 cells) were cultured in six-well
plates for 7 days in the presence or absence of 1 lM PGE2 and 1 lM
EP4 antagonist, and stained by crystal violet. Representative ﬁeld of
the stained wells (upper panel). The number of B16 colonies was
counted (lower panel). Data are expressed as the means ± S.E.M. of
three wells. (B) The expression of COX-1, COX-2, and EP4 mRNAs
was examined using B16 cells and osteoblasts (OB). Total RNA was
extracted from the cultures for RT-PCR analysis.
Fig. 4. Osteoclast formation induced by B16 cells in cocultures of
mouse bone marrow cells and osteoblasts. (A) Mouse bone marrow
cells and osteoblasts were cocultured for 7 days with ﬁxed-B16 cells in
the presence or absence of 100 nM EP4 antagonist, 1 lM indometh-
acin (Indo.), or 1 lMNS398. Representative ﬁeld of TRAP staining at
day 7 (upper panel). The number of TRAP-positive multinucleated
cells (MNCs) containing three or more nuclei was counted (lower
panel). Signiﬁcantly diﬀerent, *P < 0.01, **P < 0.001 versus control,
#P < 0.001 versus cocultured with ﬁxed-B16 cells without treatment.
Data are expressed as the means ± S.E.M. of four wells. (B) The levels
of PGE2 in the conditioned medium were determined using an EIA.
Signiﬁcantly diﬀerent, *P < 0.01, **P < 0.001 versus control,
#P < 0.001 versus cocultured with ﬁxed-B16 cells without treatment.
Data are expressed as the means ± S.E.M. of four wells. (C) The
expression of RANKL mRNA was examined by RT-PCR in coculture
of mouse osteoblasts and bone marrow cells with ﬁxed-B16 cells.
Mouse bone marrow cells and osteoblasts were cocultured for 4 days
with ﬁxed-B16 cells in the presence or absence of 100 nM EP4
antagonist, 1 lM indomethacin (Indo.), or 1 lM NS398, and total
RNA was extracted from adherent cells. The expression of RANKL
and GAPDH mRNAs was analyzed by RT-PCR. The top shows the
relative intensity of RANKL expression versus the control.
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blocks the binding of PGE2 to osteoblasts, resulting in the sup-
pression of osteoclastic bone resorption.
Previous studies have shown that PTHrP produced by cancer
cells is implicated in osteolysis due to cancer metastasis [1,2].
Then, we examined the expression of PTHrP in B16 cells, and
found no expression of PTHrP mRNA in B16 cells (data not
shown). Perez et al. also reported the lack of PTHrP production
by B16 cells [22]. Therefore, it is unlikely that PTHrP is a reg-
ulator for bone metastasis of cancer in our experimental model.
It is well known that PGE2 acts on osteoblasts and induces
the expression of RANKL to elicit osteoclastogenesis. We
have reported that PGE2 could not induce bone resorption
in organ cultures of mouse calvaria collected from EP4-null
mice, and that EP4 agonist stimulates RANKL expression in
osteoblasts and osteoclast formation in bone marrow cultures
[8,9]. Therefore, PGE2 may stimulate bone resorption by the
RANKL-dependent pathway via the EP4 receptor subtype
expressed in osteoblasts. Ono et al. [16] have shown that bone
marrow stromal cells adjacent to tumor cells express COX-2
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cell-to-cell interactions between breast cancer cells and osteo-
blasts induced the expression of COX-2 in osteoblasts [23].
In the present study, adding B16 cells could induce osteoclast
formation in the coculture of bone marrow cells and osteo-
blasts (Fig. 4). In the cocultures, B16 cells were ﬁxed with para-
formaldehyde to eliminate the inﬂuence of soluble factor(s)
produced by B16. Then, we focused on the cell-to-cell interac-
tion between B16 and osteoblasts, that was probably mediated
by cell surface molecule(s) on their membrane. In this study,
we propose a model of the mechanism by which cell-to-cell
contact between cancer cells and host osteoblasts induces
PGE2-mediated osteoclast formation in bone with osteolytic
metastasis. The contact of cancer cells with osteoblasts induces
COX-2 to produce PGE2, and PGE2 binds to the EP4 receptor
expressed in osteoblasts, resulting in the expression of
RANKL in osteoblasts to induce osteoclasts formation from
monocyte-macrophages. The PGE2-EP4 signaling may be crit-
ical for cancer-induced progression of osteoclastic bone
resorption in the bone metastasis of cancer. Further studies
are necessary to deﬁne a cell surface molecule(s) involved in
the interaction between B16 and osteoblasts, and the mecha-
nism of signal transduction after the cell-to-cell contact to pro-
duce PGE2 by osteoblasts.
Epidemiological studies and clinical observations suggest
that non-steroidal anti-inﬂammatory drugs (NSAIDs) may
reduce the risk of certain types of human cancer [12,13]. Re-
cently, Gupta et al. [24] have reported that the administration
of celecoxib, a selective COX-2 inhibitor, suppressed prostate
carcinogenesis in transgenic adenocarcinoma of the mouse
prostate model. COX-2 inhibitors have also been reported to
act as chemopreventive agents against colon carcinogenesis
[13]. NSAIDs are also known to reduce the risk of breast can-
cer, and elevated COX-2 expression was associated with tumor
size in patients with breast cancer [12]. Amano et al. [25] have
reported that implanted tumor growth associated with angio-
genesis was markedly suppressed in EP3-null mice, and that
the administration of COX-2 inhibitor reduced tumor growth
in wild-type mice.
In conclusion, the present study clearly showed that the
administration of EP4 antagonist suppressed the area of
metastasis of B16 in bone and bone loss in the metastatic re-
gion in vivo. Therefore, PGE2 produced by host osteoblasts
may be involved in osteolysis due to tumor cells. The present
study supports the development of clinical trials to determine
whether EP4 antagonist can be useful as a therapeutic agent
in the management of cancer accompanying bone metastasis.
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